QQ客服 官方微博 反馈留言

	Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo
	Su, Yongwei; Li, Xinyu; Ma, Jun; Zhao, Jianyun; Liu, Shuang; Wang, Guan; Edwards, Holly; Taub, Jeffrey W.; Lin, Hai; Ge, Yubin
刊名	BIOCHEMICAL PHARMACOLOGY
	2018
卷号	148
关键词	Acute myeloid leukemia Pl3K mTOR ERK Bcl-2
ISSN号	0006-2952
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3535185
专题	吉林大学白求恩第一医院
推荐引用方式 GB/T 7714	Su, Yongwei,Li, Xinyu,Ma, Jun,et al. Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo[J]. BIOCHEMICAL PHARMACOLOGY,2018,148.
APA	Su, Yongwei.,Li, Xinyu.,Ma, Jun.,Zhao, Jianyun.,Liu, Shuang.,...&Ge, Yubin.(2018).Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo.BIOCHEMICAL PHARMACOLOGY,148.
MLA	Su, Yongwei,et al."Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo".BIOCHEMICAL PHARMACOLOGY 148(2018).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。